Puma Biotechnology, Inc.

PBYI Healthcare Biotechnology

Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

9.83 0.69 −6.56%
Market cap
$543.0M
P/E
18.2×
Fwd P/E
24.2×
Dividend yield
—
F-score
8/9
Altman Z
−4.16
Beneish M
−2.06
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
15.02 12.78 9.44 7.08

+8 more quarters

P/S ratio
1.79 1.43 1.30 1.26
P/FCF ratio
14.46 7.92 10.18 8.80
P/Operating CF
254.39 21.08 20.64 27.59
P/B ratio
2.98 2.53 2.28 2.32
EV/Sales
1.48 1.07 1.01 1.02
EV/EBITDA
8.34 6.05 4.80 4.82
EV/FCF
11.95 5.93 7.91 7.09
Current Ratio
2.91 2.38 2.00 1.74
Net Debt/EBITDA
(9.30) 74.24 (3.90) (5.10)
Debt/Equity
0.00 0.09 0.17 0.29
Earnings Yield
6.66% 7.82% 10.59% 14.12%
Free Cash Flow Yield
6.92% 12.63% 9.82% 11.36%
Free Cash Flow per Share
0.03 0.30 0.29 0.19
Book value per Share
2.72 2.53 2.61 2.29
Free Cash Flow
1.62 15.42 14.46 9.66
EV/EBIT
11.22 8.26 6.20 6.42
Other line items

Show all line items

Columns are period end dates